Cagrisema Side Effects: What the REDEFINE Program Has Shown

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide side effects and safety hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last February, a 44-year-old woman named Rachel in Austin, Texas, walked into her obesity medicine consultation holding two pages of notes she'd printed from Reddit. She'd read that cagrisema was "basically Ozempic on steroids," that the side effects were "brutal," and that she should expect to lose 25 percent of her body weight or not bother. Her prescriber, a board-certified internist with six years of GLP-1 prescribing experience, told her that roughly half of what she'd printed was wrong, a quarter was out of context, and the rest was actually useful. "People are Googling the combination drug and thinking it describes what they're taking," the doctor told her. "Those are different products, and the confusion is doing real harm."

That confusion is exactly what this article is for.

This guide sits inside the broader Compounded Semaglutide Side Effects and Safety cluster, which is part of the compounded semaglutide pillar guide.

Cagrisema vs. Compounded Semaglutide: Why People Keep Mixing Them Up

Here's the thing: cagrisema and compounded semaglutide are not the same product. They are not even in the same regulatory category. Cagrisema is a fixed-dose combination of semaglutide with cagrilintide, an amylin analog. It's investigational. It has progressed through Novo Nordisk's REDEFINE clinical trial program but is not commercially available as of this writing. Compounded semaglutide programs do not dispense cagrisema.

Why does this matter? Because the side effect profile of a combination drug reflects two active molecules acting in concert. The gastrointestinal event rates in the REDEFINE trials are generally higher than for semaglutide monotherapy at comparable doses. That's consistent with what pharmacologists would predict: you're stacking two gut-active peptides.

If you're on compounded semaglutide, the clinical evidence that actually applies to you comes from the semaglutide monotherapy trials, primarily the STEP and SUSTAIN programs. Not the REDEFINE data. Treating one as a proxy for the other is like reading the side effects of a combination antibiotic and assuming they describe amoxicillin alone.

What the Semaglutide Trial Record Actually Tells Us

The published safety data for semaglutide is one of the more thorough datasets in obesity medicine. Full stop. Across STEP-1, STEP-3, STEP-4, SUSTAIN-6, LEADER, and SELECT, gastrointestinal events were the most common adverse effects, and serious adverse events were uncommon.

Pancreatitis showed up in a small fraction of patients across these trials. The rate did not differ significantly between active and placebo arms in SELECT or LEADER, though individual cases obviously still warrant attention.

The boxed warning on Wegovy and Ozempic labels regarding thyroid C-cell tumors is based on rodent data. Human evidence for that risk has not materialized at population scale in the large outcome trials. Most prescribers screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 before writing the prescription. That screening is fast, takes about 30 seconds of history-taking, and is non-negotiable.

Compounded semaglutide uses the same active ingredient as Wegovy and Ozempic. The clinical evidence base for the molecule applies. But compounded preparations are prepared by licensed compounding pharmacies under clinician prescription, operate under a different regulatory framework, and are not FDA-approved. They have not been independently tested in randomized trials at the same scale as the branded products. That distinction matters, and honest programs don't blur it.

The First Eight Weeks: What Most People Actually Feel

The early weeks are where the side effect conversation lives for most patients. Nausea, decreased appetite, mild bloating, constipation, intermittent reflux. Roughly 20 percent of patients in STEP-1 reported nausea at some point during the trial. Severe nausea was less common. The pattern is almost always dose-related: it appears at or shortly after a dose increase and tends to settle within one to two weeks.

Fatigue gets brought up a lot. It's a less specific symptom, and the boring truth is that it usually reflects the lower caloric intake of early therapy rather than a direct drug effect. Your body was running on 2,400 calories. Now it's running on 1,500. Of course you feel different. Patients with persistent fatigue benefit from checking basic labs, hydration status, and protein intake before blaming the medication.

The practical mitigations for GI side effects are not glamorous: small, slow meals; lower-fat content; adequate hydration; avoiding fried or very rich foods during the first two weeks after any dose change. These four interventions are the most reliable ones for tolerability. Anti-nausea medication is appropriate for some patients and is a routine prescribing option, not a sign that something has gone wrong.

When to Actually Pick Up the Phone

Most GI side effects don't require a call. But patients tend to underestimate when they should reach out, not overestimate. The threshold should be lower than you think.

Call your prescriber for:

Vomiting lasting more than one day
Severe upper abdominal pain, especially if it radiates to the back
Signs of dehydration (dark urine, dizziness, rapid heart rate)
Jaundice
Persistent severe headache or vision changes

Most garden-variety nausea, mild constipation, or reduced appetite can be managed with a dose hold or symptomatic care. But the items on that list above need a clinical conversation, not a wait-and-see approach.

Four Misconceptions That Keep Coming Up

"Compounded semaglutide has the same regulatory status as Wegovy." It does not. Compounding pharmacies operate under a different framework (503A or 503B), with different oversight. Compounded preparations are not FDA-approved. That's not a disqualifier, but it's a fact patients should understand clearly.

"Worse side effects mean the drug is working harder." Trial data don't support this. In STEP-1 and STEP-3, patients with mild GI tolerability and patients with more pronounced symptoms both achieved meaningful weight loss. Suffering is not a biomarker.

"The medication does the work for you." STEP-3 paired semaglutide with a structured lifestyle intervention and produced greater mean weight loss than STEP-1, which used the medication with standard counseling. Lifestyle is additive. My honest take: patients who treat GLP-1 therapy as a substitute for eating well and moving are setting themselves up for exactly the outcomes they're hoping to avoid.

"Stopping the medication just resets you to where you were." It's worse than that. STEP-4 documented partial weight regain over the 48 weeks after switching from active drug to placebo at week 20. The chronic biology of weight regulation reasserts itself without pharmacologic support, in the same way blood pressure climbs when you stop an antihypertensive. This is a chronic condition, and the medication treats it chronically.

What Matters More Than the Brand Name

The clinician relationship matters more than the specific program. A program that supports honest clinical conversation, responds to side effects with appropriate adjustments, and provides clear follow-up between refills produces better outcomes than one with slick marketing and weak clinical infrastructure. That's not a soft point. It's arguably the most important variable in the whole equation.

The active ingredient in compounded preparations is the same as in Wegovy and Ozempic. The clinical evidence base for the molecule applies. The regulatory status, oversight, and supply chain for compounded preparations are distinct from branded products. Individual response varies, because trial means describe averages, not individuals. And lifestyle context matters more on therapy than off it, because every calorie you do consume carries more nutritional weight when total intake is reduced. Think of it like a smaller budget: every dollar counts more.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Side Effects and Safety cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Are the side effects of compounded semaglutide different from Wegovy or Ozempic?

The active ingredient is the same. The side effect profile reported in compounded semaglutide programs mirrors what was reported in SUSTAIN, STEP-1, and STEP-3 for the branded products. Compounded preparations are not FDA-approved and have not been independently studied in the same way.

When should a side effect trigger a call to the prescriber?

Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.

Do side effects predict effectiveness?

There is no reliable evidence that nausea or other GI side effects predict greater weight loss. Trial data show meaningful weight loss in patients with minimal side effects as well as those with more.

Is cagrisema the same thing as compounded semaglutide?

No. Cagrisema is a fixed-dose investigational combination of semaglutide and cagrilintide. It is a separate product in a separate trial program (REDEFINE). Compounded semaglutide contains semaglutide alone.

Should I expect the REDEFINE side effect data to reflect my experience on compounded semaglutide?

Not directly. The REDEFINE program studied a two-molecule combination. The relevant evidence for compounded semaglutide monotherapy comes from the STEP and SUSTAIN trial programs.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.